ChromaDex/CDXC

$1.61

-2.99%
-
1D1W1MYTD1YMAX

About ChromaDex

Chromadex Corp. is a bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain its ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. It provides Niagen in ingredient form to its strategic partners. It provides Niagen in ingredient form to its strategic partners. It also offers Immulina, which is a spirulina extract. The Analytical Reference Standards and Services segment offers the supply of phytochemical reference standards and other research and development services.

Ticker

CDXC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Fried

Employees

113

Headquarters

Los angeles, United States

ChromaDex Metrics

BasicAdvanced
$120.95M
Market cap
-
P/E ratio
-$0.09
EPS
1.87
Beta
-
Dividend rate

What the Analysts think about ChromaDex

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 5 analysts.
201.24% upside
High $7.00
Low $2.00
$1.61
Current price
$4.85
Average price target

ChromaDex Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-4.63% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$19.4M
-4.43%
Net income
$-900K
-57.14%
Profit margin
-4.63%
-55.22%

ChromaDex Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 69.23%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.02
-$0.03
-$0.03
-$0.01
-
Expected
-$0.02
-$0.05
-$0.04
-$0.03
-$0.03
Surprise
-17.24%
-37.5%
-20%
-69.23%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ChromaDex stock

Buy or sell ChromaDex stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing